Log in

Relevant bibliographies by topics / Zacopride / Journal articles

To see the other types of publications on this topic, follow the link: Zacopride.

Journal articles on the topic 'Zacopride'

Author: Grafiati

Published: 4 June 2021

Last updated: 15 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Zacopride.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Lin, Yuanyuan, Junhu Li, Baozhong Zhu, et al. "Zacopride Exerts an Antiarrhythmic Effect by Specifically Stimulating the Cardiac Inward Rectifier Potassium Current in Rabbits: Exploration of a New Antiarrhythmic Strategy." Current Pharmaceutical Design 26, no. 44 (2020): 5746–54. http://dx.doi.org/10.2174/1381612826666200701135508.

Full text

Abstract:

Background: Zacopride, a potent antagonist of 5-HT3 receptors and an agonist of 5-HT4 receptors, is a gastrointestinal prokinetic agent. In a previous study, we discovered that zacopride selectively stimulated the inward rectifier potassium current (IK1) in the rat and that agonizing IK1 prevented or eliminated aconitine-induced arrhythmias in rats. Objective: Our aims were to confirm that the antiarrhythmic effects of zacopride are mediated by selectively enhancing IK1 in rabbits. Methods: The effects of zacopride on the function of the main ion channels were investigated using a whole-cell p

APA, Harvard, Vancouver, ISO, and other styles

2

Wade, P. R., G. M. Mawe, T. A. Branchek, and M. D. Gershon. "Use of stereoisomers of zacopride to analyze actions of 5-hydroxytryptamine on enteric neurons." American Journal of Physiology-Gastrointestinal and Liver Physiology 260, no. 1 (1991): G80—G90. http://dx.doi.org/10.1152/ajpgi.1991.260.1.g80.

Full text

Abstract:

Two subtypes of excitatory 5-hydroxytryptamine (5-HT) receptor, 5-HT1P and 5-HT3, are found on type 2-AH neurons of the guinea pig myenteric plexus. The 5-HT1P receptor mediates a slow and the 5-HT3 receptor a fast depolarization of these cells, however, the role of these receptors in the physiology of the gut is unknown. Renzapride (BRL 24924), a substituted benzamide, has previously been found to antagonize responses of myenteric neurons mediated by both 5-HT1P and 5-HT3 receptors. The effects on myenteric type 2-AH neurons of a structurally similar benzamide, zacopride, which unlike renzapr

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Zacopride doesn??t meet expectations." Inpharma Weekly &NA;, no. 858 (1992): 12. http://dx.doi.org/10.2165/00128413-199208580-00018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

SMITH, WILLIAM L., REEVIS S. ALPHIN, CARLOTTA B. JACKSON, and LAWRENCE F. SANCILIO. "The Antiemetic Profile of Zacopride." Journal of Pharmacy and Pharmacology 41, no. 2 (1989): 101–5. http://dx.doi.org/10.1111/j.2042-7158.1989.tb06402.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Curtis, Michael J. "Activation of IK1 by Zacopride." Journal of Cardiovascular Pharmacology 64, no. 4 (2014): 343–44. http://dx.doi.org/10.1097/fjc.0000000000000140.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Meyer, Leith C. R., Andrea Fuller, and Duncan Mitchell. "Zacopride and 8-OH-DPAT reverse opioid-induced respiratory depression and hypoxia but not catatonic immobilization in goats." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 290, no. 2 (2006): R405—R413. http://dx.doi.org/10.1152/ajpregu.00440.2005.

Full text

Abstract:

Neurophysiological studies have shown that serotonergic ligands that bind to 5-HT1A, 5-HT7, and 5-HT4 serotonin receptors in brain stem have beneficial effects on respiratory neurons during opioid-induced respiratory depression. The effect of these ligands on respiratory function and pulmonary performance has not been studied. We therefore examined the effects of 8-hydroxy-2-(di- n-propylamino)tetralin (8-OH-DPAT), an agonist of 5-HT1A and 5-HT7 receptors, and zacopride, an agonist of 5-HT4 receptors, to establish whether these ligands would reverse opioid-induced respiratory depression and hy

APA, Harvard, Vancouver, ISO, and other styles

7

SMITH, W. W., L. F. SANCILIO, J. B. OWERA-ATEPO, R. J. NAYLOR, and L. LAMBERT. "Zacopride, a potent 5-HT3 antagonist." Journal of Pharmacy and Pharmacology 40, no. 4 (1988): 301–2. http://dx.doi.org/10.1111/j.2042-7158.1988.tb05253.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ge, Jian, Janine M. Barnes, Patrick Towers, and Nicholas M. Barnes. "Distribution of S(−)-zacopride-insensitive []R(+)-zacopride binding sites in the rat brain and peripheral tissues." European Journal of Pharmacology 332, no. 3 (1997): 307–12. http://dx.doi.org/10.1016/s0014-2999(97)01091-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Laporte, A. M., T. Koscielniak, M. Ponchant, D. Vergé, M. Hamon, and H. Gozlan. "Quantitative autoradiographic mapping of 5-HT3receptors in the rat CNS using [125I]iodo-zacopride and [3H]zacopride as radioligands." Synapse 10, no. 4 (1992): 271–81. http://dx.doi.org/10.1002/syn.890100402.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Pisters, K. M. W., M. G. Kris, L. B. Tyson, R. A. Clark, and R. J. Gralla. "Dose-Ranging Trial of Zacopride: The Emetic Antiemetic?" JNCI Journal of the National Cancer Institute 84, no. 9 (1992): 717–18. http://dx.doi.org/10.1093/jnci/84.9.717.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Pinkus, Lawrence M., Nathan S. Sarbin, Dana S. Barefoot, and John C. Gordon. "Association of [3H]zacopride with 5-HT3 binding sites." European Journal of Pharmacology 168, no. 3 (1989): 355–62. http://dx.doi.org/10.1016/0014-2999(89)90797-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Makale, M. T., and G. L. King. "Surgical and pharmacological dissociation of cardiovascular and emetic responses to intragastric CuSO4." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 263, no. 2 (1992): R284—R291. http://dx.doi.org/10.1152/ajpregu.1992.263.2.r284.

Full text

Abstract:

Under control (intact and laparotomized) conditions, arterial pressure of urethan-anesthetized ferrets rose significantly in response to intragastric copper sulfate (CuSO4; 10 ml of 5 mg/ml). CuSO4 was emetic 75-90% of the time, and a cardiovascular response always immediately preceded and accompanied emetic responses. The cardiovascular response was significantly reduced or abolished by hexamethonium (0.35 mg/kg) pretreatment combined with atropine methyl bromide (1 mg/kg). Addition of the alpha 2-receptor antagonist 2,3-dichloro-alpha-methylbenzylamine HCl (DCMB, 10 mg/kg) and the beta-recep

APA, Harvard, Vancouver, ISO, and other styles

13

COSTALL, B., A. M. DOMENEY, P. A. GERRARD, M. E. KELLY, and R. J. NAYLOR. "Zacopride: anxiolytic profile in rodent and primate models of anxiety." Journal of Pharmacy and Pharmacology 40, no. 4 (1988): 302–5. http://dx.doi.org/10.1111/j.2042-7158.1988.tb05254.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Young, Richard, and David N. Johnson. "Anxiolytic-like activity of R(+)- and S(−)-zacopride in mice." European Journal of Pharmacology 201, no. 2-3 (1991): 151–55. http://dx.doi.org/10.1016/0014-2999(91)90338-q.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

File, Sandra E., and Nick Andrews. "Enhanced anxiolytic effect of zacopride enantiomers in diazepam-withdrawn rats." European Journal of Pharmacology 237, no. 1 (1993): 127–30. http://dx.doi.org/10.1016/0014-2999(93)90101-m.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Yamakuni, Hisashi, Hiroe Nakayama, Shigeo Matsui, Katsunori Imazumi, Masahiko Matsuo, and Seitaro Mutoh. "Inhibitory Effect of Zacopride on Cisplatin-Induced Delayed Emesis in Ferrets." Journal of Pharmacological Sciences 101, no. 1 (2006): 99–102. http://dx.doi.org/10.1254/jphs.scj05007x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Faustman, William O. "Zacopride in Schizophrenia: A Single-blind Serotonin Type 3 Antagonist Trial." Archives of General Psychiatry 49, no. 9 (1992): 751. http://dx.doi.org/10.1001/archpsyc.1992.01820090079013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

BARNES, N. M., B. COSTALL, and R. J. NAYLOR. "[3H]Zacopride: Ligand for the Identification of 5-HT3 Recognition Sites." Journal of Pharmacy and Pharmacology 40, no. 8 (1988): 548–51. http://dx.doi.org/10.1111/j.2042-7158.1988.tb05300.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Eglen, Richard M. "Monthly Update: The (R) zacopride binding site:Central & Peripheral Nervous Systems." Expert Opinion on Investigational Drugs 4, no. 3 (1995): 229–31. http://dx.doi.org/10.1517/13543784.4.3.229.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Ansseau, M., W. Pitchot, and A. Gonzalez Moreno. "Anxiolytic activity of single doses of the 5-HT3 antagonist zacopride." European Neuropsychopharmacology 4, no. 3 (1994): 355. http://dx.doi.org/10.1016/0924-977x(94)90177-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Boddeke, Hendrik W. G. M., and Hans O. Kalkman. "Zacopride and BRL 24924 induce an increase in EEG-energy in rats." British Journal of Pharmacology 101, no. 2 (1990): 281–84. http://dx.doi.org/10.1111/j.1476-5381.1990.tb12701.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Knapp, D. J., and L. A. Pohorecky. "Zacopride, a 5-HT3 receptor antagonist, reduces voluntary ethanol consumption in rats." Pharmacology Biochemistry and Behavior 41, no. 4 (1992): 847–50. http://dx.doi.org/10.1016/0091-3057(92)90237-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Sancilio, Lawrence F., Lawrence M. Pinkus, Carlotta B. Jackson, and H. Randall Munson. "Studies on the emetic and antiemetic properties of zacopride and its enantiomers." European Journal of Pharmacology 192, no. 3 (1991): 365–69. http://dx.doi.org/10.1016/0014-2999(91)90226-g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Sancilio, Lawrence F., Lawrence M. Pinkus, Carlotta B. Jackson, and H. Randall Munson. "Emetic activity of zacopride in ferrets and its antagonism by pharmacological agents." European Journal of Pharmacology 181, no. 3 (1990): 303–6. http://dx.doi.org/10.1016/0014-2999(90)90094-m.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Richmond, G., S. G. Potkin, L. Plon, T. McElroy, and Y. Jin. "Zacopride, A 5-HT3 receptor antagonist, may be an effective antipsychotic in schizophrenia." Schizophrenia Research 9, no. 2-3 (1993): 247–48. http://dx.doi.org/10.1016/0920-9964(93)90559-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

BARNES, NICHOLAS M., BRENDA COSTALL, JAMES W. IRONSIDE, and ROBERT L. NAYLOR. "Identification of 5-HT3 recognition sites in human brain tissue using [3H]zacopride." Journal of Pharmacy and Pharmacology 40, no. 9 (1988): 668. http://dx.doi.org/10.1111/j.2042-7158.1988.tb05338.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Barnes, J. M., N. M. Barnes, B. Costall, et al. "The differential activities of R(+)- and S(−)-zacopride as 5-HT3 receptor antagonists." Pharmacology Biochemistry and Behavior 37, no. 4 (1990): 717–27. http://dx.doi.org/10.1016/0091-3057(90)90554-u.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Mele, Paul C., John R. McDonough, David B. McLean, and Kevin P. O'Halloran. "Cisplatin-induced conditioned taste aversion: attenuation by dexamethasone but not zacopride or GR38032F." European Journal of Pharmacology 218, no. 2-3 (1992): 229–36. http://dx.doi.org/10.1016/0014-2999(92)90173-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Carley, David W., Henri Depoortere, and Miodrag Radulovacki. "R-zacopride, a 5-HT3 antagonist/5-HT4 agonist, reduces sleep apneas in rats." Pharmacology Biochemistry and Behavior 69, no. 1-2 (2001): 283–89. http://dx.doi.org/10.1016/s0091-3057(01)00535-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Zhai, Xuwen, Xi Qiao, Li Zhang, et al. "IK1 channel agonist zacopride suppresses ventricular arrhythmias in conscious rats with healing myocardial infarction." Life Sciences 239 (December 2019): 117075. http://dx.doi.org/10.1016/j.lfs.2019.117075.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Fletcher, Stephanie, and Nicholas M. Barnes. "Autoradiographic localization of the [3H]-(S)-zacopride labelled 5-HT3 receptor in porcine brain." Neuroscience Letters 269, no. 2 (1999): 91–94. http://dx.doi.org/10.1016/s0304-3940(99)00429-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Smith, William L., Esther M. Callaham, and Reevis S. Alphin. "The emetic activity of centrally administered cisplatin in cats and its antagonism by zacopride." Journal of Pharmacy and Pharmacology 40, no. 2 (1988): 142–43. http://dx.doi.org/10.1111/j.2042-7158.1988.tb05202.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Zhang, Li, QingHua Liu, ChengFang Liu, et al. "Zacopride selectively activates the Kir2.1 channel via a PKA signaling pathway in rat cardiomyocytes." Science China Life Sciences 56, no. 9 (2013): 788–96. http://dx.doi.org/10.1007/s11427-013-4531-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Young, Richard, and Richard A. Glennon. "Zacopride and its optical isomers produce stereoselective antagonism of a 2-methylserotonin discriminative stimulus." European Journal of Pharmacology 212, no. 1 (1992): 117–19. http://dx.doi.org/10.1016/0014-2999(92)90083-g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Barnes, Nicholas M., Brenda Costall, Jian Ge, M. Elizabeth Kelly, and Robert J. Naylor. "The interaction of R(+)- and S(-)-zacopride with PCPA to modify rodent aversive behaviour." European Journal of Pharmacology 218, no. 1 (1992): 15–25. http://dx.doi.org/10.1016/0014-2999(92)90142-q.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Barnes, Nicholas M., Celine H. K. Cheng, Brenda Costall, Jian Ge, M. Elizabeth Kelly, and Robert J. Naylor. "Profiles of interaction of R(+)/S(-)-zacopride and anxiolytic agents in a mouse model." European Journal of Pharmacology 218, no. 1 (1992): 91–100. http://dx.doi.org/10.1016/0014-2999(92)90151-s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Parker, Rachel M. C., Janine M. Barnes, Jian Ge, Peter C. Barber, and Nicholas M. Barnes. "Autoradiographic distribution of [ 3 H]-(S)-zacopride-labelled 5-HT 3 receptors in human brain." Journal of the Neurological Sciences 144, no. 1-2 (1996): 119–27. http://dx.doi.org/10.1016/s0022-510x(96)00211-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Wu, Bei, Cun Long, Feilong Hei, and Shilei Wang. "The Protective Effect of St. Thomas Cardioplegia Enriched With Zacopride on the Isolated Rat Heart." Artificial Organs 37, no. 1 (2012): E44—E50. http://dx.doi.org/10.1111/j.1525-1594.2012.01547.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Zhai, Xu-Wen, Li Zhang, Yun-Fei Guo, et al. "The IK1/Kir2.1 channel agonist zacopride prevents and cures acute ischemic arrhythmias in the rat." PLOS ONE 12, no. 5 (2017): e0177600. http://dx.doi.org/10.1371/journal.pone.0177600.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Wu, Bo-Wei. "Activation of IK1 Channel by Zacopride Attenuates Left Ventricular Remodeling in Rats With Myocardial Infarction." Journal of Cardiovascular Pharmacology 65, no. 3 (2015): 296. http://dx.doi.org/10.1097/01.fjc.0000462727.05737.2c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Liu, Cheng-Fang, Qing-Hua Liu, En-Li Liu, et al. "Activation of IK1 Channel by Zacopride Attenuates Left Ventricular Remodeling in Rats With Myocardial Infarction." Journal of Cardiovascular Pharmacology 64, no. 4 (2014): 345–56. http://dx.doi.org/10.1097/fjc.0000000000000127.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Wu, Bo-Wei, and Ji-Min Cao. "On the Risk Concerns of Zacopride, a Moderate IK1 Channel Agonist With Cardiac Protective Action." Journal of Cardiovascular Pharmacology 64, no. 4 (2014): 357–59. http://dx.doi.org/10.1097/fjc.0000000000000148.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Bourdin, Céline M., Jacques Lebreton, Monique Mathé-Allainmat та Steeve H. Thany. "Pharmacological profile of zacopride and new quaternarized fluorobenzamide analogues on mammalian α7 nicotinic acetylcholine receptor". Bioorganic & Medicinal Chemistry Letters 25, № 16 (2015): 3184–88. http://dx.doi.org/10.1016/j.bmcl.2015.05.094.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Fletcher, Stephanie, and Nicholas M. Barnes. "Distribution and characterisation of the [3H](S)-zacopride labelled 5-HT3 receptor in pig forebrain." Brain Research 729, no. 2 (1996): 281–84. http://dx.doi.org/10.1016/0006-8993(96)00589-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Ponchant, M., T. Koscielniak, M. Hamon, and H. Gozlan. "Synthesis of 5-[125I]-iodo-zacopride, a new probe for 5-HT3 receptor binding sites." Journal of Labelled Compounds and Radiopharmaceuticals 29, no. 10 (1991): 1147–55. http://dx.doi.org/10.1002/jlcr.2580291007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Pinkus, Lawrence M., Nathan S. Sarbin, John C. Gordon, and H. Randall Munson. "Antagonism of [3H]zacopride binding to 5-HT3 recognition sites by its (R) and (S) enantiomers." European Journal of Pharmacology 179, no. 1-2 (1990): 231–35. http://dx.doi.org/10.1016/0014-2999(90)90425-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Bill, David J., James Coleman, Ian Hallett, Vicki C. Middlefell, Keith F. Rhodes, and Allan Fletcher. "The enantiomers of zacopride: an intra-species comparison of their potencies in functional and anxiolytic models." British Journal of Pharmacology 115, no. 5 (1995): 775–80. http://dx.doi.org/10.1111/j.1476-5381.1995.tb15000.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Middlefell, Vicki C., and Tracey L. Price. "5-HT3 receptor agonism may be responsible for the emetic effects of zacopride in the ferret." British Journal of Pharmacology 103, no. 1 (1991): 1011–12. http://dx.doi.org/10.1111/j.1476-5381.1991.tb12292.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

McNeish, Charles S., Adena L. Svingos, Robert Hitzemann, and Robert E. Strecker. "The 5-HT3 antagonist zacopride attenuates cocaine-induced increases in extracellular dopamine in rat nucleus accumbens." Pharmacology Biochemistry and Behavior 45, no. 4 (1993): 759–63. http://dx.doi.org/10.1016/0091-3057(93)90118-d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Lefebvre, H., V. Contesse, C. Delarue, J. M. Kuhn, H. Vaudry, and L. M. Wolf. "Lack of effect of the serotonin 4 receptor agonist zacopride on ACTH secretion in normal men." European Journal of Clinical Pharmacology 51, no. 1 (1996): 49–51. http://dx.doi.org/10.1007/s002280050159.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!